Spero Therapeutics (FRA:2HA) ROE % Adjusted to Book Value : -87.14% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics ROE % Adjusted to Book Value?

Spero Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -92.37%. Spero Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 1.06. Spero Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -87.14%.

Spero Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Spero Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics ROE % Adjusted to Book Value Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-24.82

-16.57

-15.56

-50.86

34.72

Spero Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-20.18	356.55	-52.06	-93.43	-87.14

Competitive Comparison of Spero Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Spero Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's ROE % Adjusted to Book Value falls into.

Spero Therapeutics ROE % Adjusted to Book Value Calculation

Spero Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	24.65%	/	0.71
	=	34.72%

Spero Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-92.37%	/	1.06
	=	-87.14%

Spero Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

SPRO:USA 2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines